Literature DB >> 6598017

Disability rating scales in multiple sclerosis.

J F Kurtzke.   

Abstract

The International Federation of Multiple Sclerosis Societies has been attempting to define a Minimal Data Set for multiple sclerosis following the tripartite scheme of the World Health Organization, with one rating scheme for neurologic signs, one for physical disabilities, and one for the societal impact of the disease. Current recommendations are the Disability Status Scale or the Expanded DSS plus Functional Systems for the first, Incapacity Status Scale of 16 items for the second, and Environmental Status Scale of 7 items for the third. All are graded in an ordinal (rank) scale from 0 (normal) with larger numbers for greater involvement. ISS scores range from 0-4 and ESS from 0-5 for each item. The only part of this scheme useful for measurement in clinical trials is the (E)DSS + FS. The DSS ranges from 0-10; EDSS subdivides each DSS grade 1-9 into two. FS are pyramidal, cerebellar, brain stem, sensory, bowel and bladder, visual, cerebral, or other; all save the last are graded 0-5 or 0-6. The DSS correlates well with both frequency and severity of involvement in all FS, which in turn represent a coded standard neurologic examination.

Entities:  

Mesh:

Year:  1984        PMID: 6598017     DOI: 10.1111/j.1749-6632.1984.tb14805.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

1.  MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial.

Authors:  P Grossman; L Kappos; H Gensicke; M D'Souza; D C Mohr; I K Penner; C Steiner
Journal:  Neurology       Date:  2010-09-28       Impact factor: 9.910

Review 2.  Issues for clinical drug development in neurodegenerative diseases.

Authors:  Michel Dib
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study.

Authors:  R Heun; U Sliwka; H Rüttinger; K Schimrigk
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

4.  User interface of a teleradiology system for the MR assessment of multiple sclerosis.

Authors:  G Luccichenti; F Cademartiri; A Pichiecchio; E Bontempi; U Sabatini; S Bastianello
Journal:  J Digit Imaging       Date:  2009-07-15       Impact factor: 4.056

5.  Deep gray matter and fatigue in MS: a T1 relaxation time study.

Authors:  G Niepel; Ch R Tench; P S Morgan; N Evangelou; D P Auer; C S Constantinescu
Journal:  J Neurol       Date:  2006-03-13       Impact factor: 4.849

6.  Brain Function Assessment of Patients with Multiple Sclerosis in the Expanded Disability Status Scale: A Proposal for Modification.

Authors:  Ricardo N Alonso; Maria B Eizaguirre; Berenice Silva; Maria C Pita; Cecilia Yastremiz; Sandra Vanotti; Fernando Cáceres; Orlando Garcea
Journal:  Int J MS Care       Date:  2020 Jan-Feb

7.  Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Authors:  Gabrielle Macaron; Brandon P Moss; Hong Li; Laura E Baldassari; Stephen M Rao; David Schindler; Jay L Alberts; Malory Weber; Malissa Ayers; François Bethoux; Adrienne Boissy; Desiree Chizmadia; Devon S Conway; Charlene Fink; Robert J Fox; Shauna Gales; Bethany Green; Claire Hara-Cleaver; Neal Jordan; Kedar R Mahajan; Marisa P McGinley; Deborah M Miller; Marie Namey; Alexander Rae-Grant; Mary Rensel; Hilary Young; Mary A Willis; Daniel Ontaneda; Jeffrey A Cohen; Robert A Bermel
Journal:  Neurol Clin Pract       Date:  2020-06

8.  Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Authors:  J Das; J A Snowden; J Burman; M S Freedman; H Atkins; M Bowman; R K Burt; R Saccardi; C Innocenti; S Mistry; P J Laud; H Jessop; B Sharrack
Journal:  Mult Scler       Date:  2021-02-10       Impact factor: 6.312

Review 9.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

10.  Five-day regimen of intramuscular or subcutaneous self-administered adrenocorticotropic hormone gel for acute exacerbations of multiple sclerosis: a prospective, randomized, open-label pilot trial.

Authors:  James P Simsarian; Carol Saunders; D Michelle Smith
Journal:  Drug Des Devel Ther       Date:  2011-07-11       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.